Aims: The relative contribution of basal hyperglycaemia (BHG) and postprandial hyperglycaemia (PPHG) in type 2 diabetes patients treated with multiple daily injections (MDI) of insulin is poorly documented. In this study, the BHG and PPHG of patients from the OPT2mise study who were initially treated with MDI were assessed before randomization and again after 6 months of continuous subcutaneous insulin infusion (CSII). were compared with analysis of variance based on contribution to total hyperglycaemia in HbA1c groups (Group 1, <8%; Group 2, 8%-8.4%; Group 3, 8.5%-8.9%; Group 4, 9%-9.4%; Group 5, ≥9.5%). Changes in AUC-B and AUC-P were assessed after 6 months of pump therapy in 131 randomized participants with available CGM recordings.
| INTRODUCTION
Many patients with advanced type 2 diabetes require insulin therapy and, in most cases, a single injection of a basal insulin analog can adequately achieve the glycated haemoglobin A1c (HbA1c) target. 1 However, failure in the basal insulin regimen occurs in 42% to 67% of patients, [2] [3] [4] [5] and a multiple daily injection (MDI) regimen, combining a long-acting and a short-acting insulin, may be offered. 1 This combination therapy does not always result in tight glucose control. 3, 6, 7 A better understanding of the precise patterns of these hyperglycaemic states may, therefore, help the physician in choosing the best therapeutic options for controlling hyperglycaemia.
The concept of postprandial and fasting (also called basal) hyperglycaemic contribution to overall hyperglycaemia was first proposed by Monnier et al. in a large cohort of patients with type 2 diabetes who were treated by diet, with or without oral hypoglycaemic agents (OHA) . The authors demonstrated that the relative contribution of basal hyperglycaemia (BHG) and postprandial hyperglycaemia (PPHG) components to overall hyperglycaemic exposure differed according to the level of glucose control. Specifically, PPHG was predominant in moderate hyperglycaemic states while BHG contributed to 70% of overall hyperglycaemia in the most severe hyperglycaemic states. 8 These data were confirmed in more recent studies, [9] [10] [11] [12] and were extended in another study in which injection of a long-acting insulin analog dramatically reduced the basal component of hyperglycaemia exposure. 13 In the present study, we evaluated the extent to which BHG and PPHG contributed to overall hyperglycaemia exposure in patients from the OPT2mise trial 14 who were undergoing MDI therapy at randomization and after switching to continuous subcutaneous insulin infusion (CSII) therapy.
| MATERIALS AND METHODS
OPT2mise (ClinicalTrials.gov, number NCT01182493) was a multicentre, international, randomized, controlled, parallel-group study to evaluate the comparative efficacy and safety of CSII therapy (MiniMed Veo system, Medtronic, Northridge, California) vs MDI therapy in patients with insulin-requiring type 2 diabetes who were originally titrated with a basal-bolus insulin regimen but did not reach optimal glucose control. Briefly, patients with poor glycaemic control while undergoing MDI therapy (n = 495) were enrolled in an 8-week run-in period for insulin dose optimization (≥0.7 and ≤1.8 U/kg/d). Those with HbA1c ≥ 8% (64 mmol/mol) and ≤ 12% (108 mmol/mol) were then randomly assigned to CSII therapy or continuing MDI therapy for 6 months (n = 331). CGM data were recorded, blinded, for 6 days at baseline and at the end of 6 months of CSII therapy, using the Medtronic iPro2 CGM system (Medtronic). The primary endpoint was between-group difference in change in mean HbA1c from baseline to the end of the CSII therapy period. [14] [15] [16] [17] In this post hoc analysis, data from the OPT2mise study were used to perform different evaluations on BHG and PPHG ( Figure S1 ).
First, run-in CGM data from 259 patients undergoing MDI therapy (Study Cohort 1) were used to assess the association between baseline HbA1c subgroup levels and hyperglycaemic CGM parameters as defined below. After separating patients into 5 groups according to Figure S2 ), responders to CSII therapy were defined as participants with an HbA1c reduction >0.5% when baseline HbA1c was 8% to 8.5%
(64-69 mmol/mol), >0.7% when baseline HbA1c was 8.6% to 9.2%
(70-77 mmol/mol) and >1% when baseline HbA1c was >9.2%
(77 mmol/mol). Baseline hyperglycaemic parameters were compared between responders (n = 83) and non-responders to CSII therapy (n = 48). In a sensitivity analysis using mixed models, the results were comparable to those of an ANOVA test. All tests were 2-sided, and those below 0.05 were considered statistically significant. 3 | RESULTS
| Characteristics of the study population
Demographic and baseline characteristics of the patients from Study Cohort 1 are depicted in Table 1 and did not differ from those of the entire OPT2mise cohort. Mean baseline HbA1c was 8.9% AE 0.8%
(74 mmol/mol) in Study Cohort 1 and was comparable to that of the entire OPT2mise cohort (Table 1) . Demographic and baseline characteristics according to baseline HbA1c subgroups are depicted in Table S1 . The 24-hour CGM profiles among HbA1c subgroups are depicted in Figure S3 and suggest an incremental influence of basal hyperglycaemia from the lowest to the highest HbA1c subgroup. CGM variables, including time in range (TIR) (glucose level, 70-180 mg/dL), time above threshold (TAT) (glucose level, >180 mg/dL) and time below threshold (TBT) (glucose level, <70 mg/dL) have been described elsewhere. AUC-B increased gradually among HbA1c groups and was significantly higher in Group 5 (HbA1c ≥ 9.5) compared to Group 1 (P = .0002) to Group 4 (P = .0138). In contrast, overall AUC-P did not 
| Effect of CSII therapy on changes in HbA1c and basal and postprandial hyperglycaemia
Demographic and baseline characteristics of the patients from Study
Cohort 2 are depicted in Table 1 and did not differ from those of the patients from Study Cohort 1. At 6 months after the switch from MDI to CSII therapy, mean HbA1c had decreased from 9.0% AE 0.77%
(75 mmol/mol) to 7.9% AE 0.98% (63 mmol/mol) (mean difference, −1.1%; P = .0001). The decrease in HbA1c was significant for all HbA1c groups, ranging from −0.5% to −2.1% (Group 2 vs Group 5; P = .0001) ( Figure S2 ). The CGM hyperglycaemic parameters (ie, AUC-B, AUC-P and PPHG-RC) at baseline did not differ among Study Cohort 1, Study Cohort 2 and the cohort of patients who remained on MDI therapy (data not shown). After the switch from MDI to CSII, AUC-B decreased by 21% (P = .0007), the decrease being more pronounced (32% decrease; P < .001) in the HbA1c group ≥9.5% (80 mmol/mol) compared to other HbA1c groups ( Figure 3A ). AUC-P decreased by 17% (P < .05) after switching to CSII therapy ( Figure 3B ). PPHG-RC marginally increased by 4% in the entire cohort after switching to CSII therapy (data not shown); this was explained mainly by the increase in the highest HbA1c group (P = .05). When examining correlations after 6 months of CSII therapy between hyperglycaemic AUC on one hand, and CGM metrics and HbA1c on the other, similar correlations were observed in comparison with baseline evaluation (Table 2) .
When considering the response to CSII therapy, the percentage of responders was 53.2% in the baseline HbA1c 8% to 8.5%
(64-69 mmol/mol) group, 65.9% in the HbA1c 8.6% to 9.2%
(70-77 mmol/mol) group and 72.1% in the HbA1c > 9.2% to 12%
(77-107 mmol/mol) group. There was no statistically significant difference in baseline hyperglycaemic CGM parameters (ie, AUC-B, AUC-P and PPHG-RC) between responders and non-responders to CSII therapy (data not shown). Notably, treatment with the long-acting insulin glargine resulted in a dramatic reduction in overall hyperglycaemia, facilitated mainly by the BHG component, while the PPHG-RC increased to 50% to 60% of hyperglycaemia exposure.
13
Intensified insulin therapy has been proposed for hyperglycaemic states not controlled by therapy with a combination of basal insulin and a GLP-1 receptor agonist and an OHA. The standard of care for MDI therapy combines a long-acting and a rapid-acting insulin analog, 1 but even this insulin regimen may not allow all patients to reach the glucose target. 3, 6, 7 Understanding the factors that contribute to hyperglycaemia in situations of MDI failure may help to determine the most appropriate treatment option for improving glucose control. This issue has been poorly studied and little data on the respective involvement of basal and postprandial components of hyperglycaemic exposure are available. Several studies have reported that neither fasting plasma glucose nor 2-hour postprandial glucose were at target levels in patients with type 2 diabetes who were undergoing MDI therapy that involved high doses of insulin. 3, 6, 21 There are no available data on the level of exposure to hyperglycaemia during the fasting and the postprandial periods at this stage of the disease.
CGM data from the OPT2mise study allowed us to examine 24-hour glucose profiles in a large number of patients with advanced type 2 diabetes who were undergoing an intensified basal-bolus regimen.
14 Their profiles were characterized by an elevated 24-hour mean glucose concentration, although the basal and postprandial hyperglycaemic components were not characterized.
17
In the present work, we demonstrate that the BHG contribution predominates across a large range of HbA1c levels, from <8%
(64 mmol/mol) to >9.5% (80 mmol/mol), and represents~80% of hyperglycaemia exposure in patients with the highest HbA1c levels. In contrast, PPHG accounts for only 20% to 30% of overall hyperglycaemia, regardless of the baseline HbA1c level. These data clearly show that failure of intensified MDI therapy results mainly from the inability of high-dose long-acting insulin to control BHG. Therefore, the main therapeutic goal would be to target BHG. Several antidiabetic agents are available to achieve such a goal. Maintenance of metformin at the highest tolerated dose is widely used at each step in the pharmacological management of hyperglycaemia in type 2 diabetes, 1 including intensification of basal insulin therapy with either a short-acting insulin or a GLP-1 receptor agonist. 14, [21] [22] [23] [24] [25] Addition of a long-acting GLP-1 receptor agonist to a regimen of multiple daily injections or to CSII therapy aims to control BHG and was proven to be effective in recent trials. 21, 22 Other agents, such as glitazones and SGLT-2 inhibitors, may also be added to intensified insulin therapy in order to increase glycaemic control and/or to limit weight gain. [26] [27] [28] After enrolment in the OPT2mise trial, patients who failed to respond to an 8-week run-in period with basal-bolus insulin therapy and were then randomized to CSII therapy showed a dramatic reduction in HbA1c level. The reduction was even greater for the highest baseline HbA1c level. 14, 16 Both BHG and PPHG were decreased by CSII therapy, resulting in a stable basal-to-postprandial hyperglycaemic ratio of 70%/30% before and after 6 months of CSII therapy. It should be noted that this improvement was achieved despite a 20%
lower dose of total daily insulin with CSII therapy compared with MDI therapy, 14 highlighting the efficacy of CSII delivery compared to that of MDI.
Potential predictive factors that may help in identifying responders to CSII therapy have been assessed. In a previous OpT2-mise trial analysis, the only factors associated with a decrease in HbA1c with CSII therapy were the baseline level of HbA1c and a lower variability in baseline glucose values with CGM recordings.
29
The present study did not identify BHG or PPHG as predictors of the response to pump therapy.
Several limitations to these post-hoc analyses must be mentioned.
Firstly, the number of patients for whom data for the exploratory glucose profile analysis were available did not represent the full OpT2-mise cohort. However, the demographic and treatment characteristics of the 2 study cohorts did not differ from those of the entire OpT2-mise cohort. Secondly, the number of patients per subgroup, based on baseline HbA1c level, was small and not all CGM data for this group constituted full 6-day recordings, thus limiting the validity of the analysis. Lastly, the actual meal times for each participant were not available; therefore, a less precise method of defining the postprandial component of overall hyperglycaemia was used.
Despite these limitations, the present study demonstrates that BHG rather than PPHG is the major determinant of overall hyperglycaemic exposure in patients with advanced type 2 diabetes who fail to respond to an intensified MDI regimen. CSII therapy appears to reduce the basal component of overall hyperglycaemic exposure at HbA1c levels above 8% (64 mmol/mol). The addition of OHAs that also target BHG may help to further optimize glucose control in uncontrolled type 2 diabetes.
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